News
By triggering weight loss using the likes of Ozempic, people can expect various possible changes to their appearance ...
1h
Flow Space on MSNHow Soon Will We Be Able to Take GLP-1s in Pill Form?Why Might Some People Opt to Take an Oral Version of Wegovy Instead of Injections? There are multiple reasons why someone ...
Early-stage study results suggest that a single shot of the company’s therapy, which works differently than GLP-1 medicines, ...
Activist hedge fund Parvus Asset Management is building a stake in Novo Nordisk , after the company lost its first mover ...
S&P 500, Eli Lilly and Company, Novo Nordisk A/S Class B, Novo Nordisk A/S. Read 's Market Analysis on Investing.com ...
Shares of weight-loss drug developer Metsera gained as much as 25% on Monday after the company's experimental drug helped patients lose weight in a small, early-stage trial, showing potential for a ...
Sanofi boosts Beyfortus output for RSV season while Dupixent trial shows strong eczema relief in patients with skin of color.
In the UK, anxiety, panic attacks and insomnia are not listed as possible side-effects for Ozempic, Wegovy or Mounjaro.
WEIGHT loss jabs could prevent a medication taken by millions of women from working – and increase patients’ risk of cancer. The British Menopause Society said the jabs could cause ...
5h
Investor's Business Daily on MSNObesity Newcomer Metsera, Up 23%, Enters The Ring With A PunchMetsera stock surged Monday after the drugmaker unveiled "solid" results for a potential monthly shot to stoke weight loss.
Chugai plans to pair its muscle-preserving drug with Eli Lilly's orforglipron, addressing muscle loss in obesity care as the ...
Novo Nordisk's GLP-1 agonist semaglutide, used to treat diabetes and obesity, may cause a serious eye condition that can lead ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results